Small Cell Lung Cancer: Patterns of care and their influence on survival - 25years experience of a single Australian oncology unit

Sarwan Bishnoi, Kenneth Pittman, Margaret Colbeck, Amanda Townsend, Jennifer Hardingham, Shawgi Sukumaran, Beverley Hooper, Margaret Tuck, David Roder, Colin Luke, Timothy Price

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aim: Evidence supporting improved outcomes for small cell lung cancer (SCLC) in recent decades is limited. This study aimed to identify patterns of care and survival over two time periods; 1 January 1987 to 31 December 1996 (cohort A) and 1 January 1997 to 31 December 2006 9 (cohort B). Methods: Patients' characteristics, management and outcome data were extracted from the Hospital Cancer Registry and clinical records. Survival analysis was determined using the Kaplan-Meier method and the log-rank test. Factors influencing survival outcome were assessed using Cox proportional hazards regression. Results: The total number of patients was 392 (224 in cohort A, 168 in cohort B). Overall 38% patients in cohort A and 24% in cohort B had limited stage (LS) disease at diagnosis. Combined chemoradiotherapy for LS increased from 5% in cohort A to 65% in cohort B. Overall 19% of patients in cohort A and 24% in cohort B received symptomatic treatment alone (STA). Median survival for LS in cohort B was significantly higher (19.5months), than in cohort A (11.8months) (P=0.03). In extensive stage (ES) disease, median survival was 6.2months in cohort A and 4.3months in cohort B (P=0.7). Variables for poorer outcome were STA, male gender, poor performance status, ES and whether the diagnosis was made in the earlier time period in cohort A. Conclusion: Outcomes for LS SCLC have improved with combined chemoradiotherapy, in keeping with worldwide data. The trends may also reflect recent improvements in staging and standardization of treatment. The outcome for ES-SCLC remains poor.

LanguageEnglish
Pages252-257
Number of pages6
JournalAsia-Pacific Journal of Clinical Oncology
Volume7
Issue number3
DOIs
Publication statusPublished - Sep 2011
Externally publishedYes

Keywords

  • Chemotherapy
  • Lung cancer
  • Radiotherapy
  • SCLC

ASJC Scopus subject areas

  • Oncology

Cite this

Bishnoi, Sarwan ; Pittman, Kenneth ; Colbeck, Margaret ; Townsend, Amanda ; Hardingham, Jennifer ; Sukumaran, Shawgi ; Hooper, Beverley ; Tuck, Margaret ; Roder, David ; Luke, Colin ; Price, Timothy. / Small Cell Lung Cancer : Patterns of care and their influence on survival - 25years experience of a single Australian oncology unit. In: Asia-Pacific Journal of Clinical Oncology. 2011 ; Vol. 7, No. 3. pp. 252-257.
@article{20d1e77875074831abd099f1d8a7d6e4,
title = "Small Cell Lung Cancer: Patterns of care and their influence on survival - 25years experience of a single Australian oncology unit",
abstract = "Aim: Evidence supporting improved outcomes for small cell lung cancer (SCLC) in recent decades is limited. This study aimed to identify patterns of care and survival over two time periods; 1 January 1987 to 31 December 1996 (cohort A) and 1 January 1997 to 31 December 2006 9 (cohort B). Methods: Patients' characteristics, management and outcome data were extracted from the Hospital Cancer Registry and clinical records. Survival analysis was determined using the Kaplan-Meier method and the log-rank test. Factors influencing survival outcome were assessed using Cox proportional hazards regression. Results: The total number of patients was 392 (224 in cohort A, 168 in cohort B). Overall 38{\%} patients in cohort A and 24{\%} in cohort B had limited stage (LS) disease at diagnosis. Combined chemoradiotherapy for LS increased from 5{\%} in cohort A to 65{\%} in cohort B. Overall 19{\%} of patients in cohort A and 24{\%} in cohort B received symptomatic treatment alone (STA). Median survival for LS in cohort B was significantly higher (19.5months), than in cohort A (11.8months) (P=0.03). In extensive stage (ES) disease, median survival was 6.2months in cohort A and 4.3months in cohort B (P=0.7). Variables for poorer outcome were STA, male gender, poor performance status, ES and whether the diagnosis was made in the earlier time period in cohort A. Conclusion: Outcomes for LS SCLC have improved with combined chemoradiotherapy, in keeping with worldwide data. The trends may also reflect recent improvements in staging and standardization of treatment. The outcome for ES-SCLC remains poor.",
keywords = "Chemotherapy, Lung cancer, Radiotherapy, SCLC",
author = "Sarwan Bishnoi and Kenneth Pittman and Margaret Colbeck and Amanda Townsend and Jennifer Hardingham and Shawgi Sukumaran and Beverley Hooper and Margaret Tuck and David Roder and Colin Luke and Timothy Price",
year = "2011",
month = "9",
doi = "10.1111/j.1743-7563.2011.01426.x",
language = "English",
volume = "7",
pages = "252--257",
journal = "Asia-Pacific Journal of Clinical Oncology",
issn = "1743-7555",
publisher = "Wiley-Blackwell",
number = "3",

}

Bishnoi, S, Pittman, K, Colbeck, M, Townsend, A, Hardingham, J, Sukumaran, S, Hooper, B, Tuck, M, Roder, D, Luke, C & Price, T 2011, 'Small Cell Lung Cancer: Patterns of care and their influence on survival - 25years experience of a single Australian oncology unit', Asia-Pacific Journal of Clinical Oncology, vol. 7, no. 3, pp. 252-257. https://doi.org/10.1111/j.1743-7563.2011.01426.x

Small Cell Lung Cancer : Patterns of care and their influence on survival - 25years experience of a single Australian oncology unit. / Bishnoi, Sarwan; Pittman, Kenneth; Colbeck, Margaret; Townsend, Amanda; Hardingham, Jennifer; Sukumaran, Shawgi; Hooper, Beverley; Tuck, Margaret; Roder, David; Luke, Colin; Price, Timothy.

In: Asia-Pacific Journal of Clinical Oncology, Vol. 7, No. 3, 09.2011, p. 252-257.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Small Cell Lung Cancer

T2 - Asia-Pacific Journal of Clinical Oncology

AU - Bishnoi, Sarwan

AU - Pittman, Kenneth

AU - Colbeck, Margaret

AU - Townsend, Amanda

AU - Hardingham, Jennifer

AU - Sukumaran, Shawgi

AU - Hooper, Beverley

AU - Tuck, Margaret

AU - Roder, David

AU - Luke, Colin

AU - Price, Timothy

PY - 2011/9

Y1 - 2011/9

N2 - Aim: Evidence supporting improved outcomes for small cell lung cancer (SCLC) in recent decades is limited. This study aimed to identify patterns of care and survival over two time periods; 1 January 1987 to 31 December 1996 (cohort A) and 1 January 1997 to 31 December 2006 9 (cohort B). Methods: Patients' characteristics, management and outcome data were extracted from the Hospital Cancer Registry and clinical records. Survival analysis was determined using the Kaplan-Meier method and the log-rank test. Factors influencing survival outcome were assessed using Cox proportional hazards regression. Results: The total number of patients was 392 (224 in cohort A, 168 in cohort B). Overall 38% patients in cohort A and 24% in cohort B had limited stage (LS) disease at diagnosis. Combined chemoradiotherapy for LS increased from 5% in cohort A to 65% in cohort B. Overall 19% of patients in cohort A and 24% in cohort B received symptomatic treatment alone (STA). Median survival for LS in cohort B was significantly higher (19.5months), than in cohort A (11.8months) (P=0.03). In extensive stage (ES) disease, median survival was 6.2months in cohort A and 4.3months in cohort B (P=0.7). Variables for poorer outcome were STA, male gender, poor performance status, ES and whether the diagnosis was made in the earlier time period in cohort A. Conclusion: Outcomes for LS SCLC have improved with combined chemoradiotherapy, in keeping with worldwide data. The trends may also reflect recent improvements in staging and standardization of treatment. The outcome for ES-SCLC remains poor.

AB - Aim: Evidence supporting improved outcomes for small cell lung cancer (SCLC) in recent decades is limited. This study aimed to identify patterns of care and survival over two time periods; 1 January 1987 to 31 December 1996 (cohort A) and 1 January 1997 to 31 December 2006 9 (cohort B). Methods: Patients' characteristics, management and outcome data were extracted from the Hospital Cancer Registry and clinical records. Survival analysis was determined using the Kaplan-Meier method and the log-rank test. Factors influencing survival outcome were assessed using Cox proportional hazards regression. Results: The total number of patients was 392 (224 in cohort A, 168 in cohort B). Overall 38% patients in cohort A and 24% in cohort B had limited stage (LS) disease at diagnosis. Combined chemoradiotherapy for LS increased from 5% in cohort A to 65% in cohort B. Overall 19% of patients in cohort A and 24% in cohort B received symptomatic treatment alone (STA). Median survival for LS in cohort B was significantly higher (19.5months), than in cohort A (11.8months) (P=0.03). In extensive stage (ES) disease, median survival was 6.2months in cohort A and 4.3months in cohort B (P=0.7). Variables for poorer outcome were STA, male gender, poor performance status, ES and whether the diagnosis was made in the earlier time period in cohort A. Conclusion: Outcomes for LS SCLC have improved with combined chemoradiotherapy, in keeping with worldwide data. The trends may also reflect recent improvements in staging and standardization of treatment. The outcome for ES-SCLC remains poor.

KW - Chemotherapy

KW - Lung cancer

KW - Radiotherapy

KW - SCLC

UR - http://www.scopus.com/inward/record.url?scp=80052227813&partnerID=8YFLogxK

U2 - 10.1111/j.1743-7563.2011.01426.x

DO - 10.1111/j.1743-7563.2011.01426.x

M3 - Article

VL - 7

SP - 252

EP - 257

JO - Asia-Pacific Journal of Clinical Oncology

JF - Asia-Pacific Journal of Clinical Oncology

SN - 1743-7555

IS - 3

ER -